GE HealthCare completes Phase I trials for a safe MRI contrast agent alternative to gadolinium.

GE HealthCare has completed Phase I trials for a novel macrocyclic manganese-based MRI contrast agent, which showed a favorable safety profile with no serious adverse events. This agent offers comparable imaging capabilities to gadolinium-based agents but could mitigate concerns over gadolinium retention and environmental impact. If successful in further development, it may enhance safety for vulnerable patients and expand treatment options in MRI imaging.

October 07, 2024
5 Articles

Further Reading